MAGED1

Across TCGA pan-cancer cohorts, MAGED1 RNA is linked to patient survival in 25 of 34 cancer types, making it the most broadly survival-associated MAGED1 data layer compared with 7 for mutation status and 6 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher MAGED1 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MAGED1 expression acts as an unfavorable survival marker, although some lineages such as PAAD and ACC show a favorable association.

STAD, UVM, and BLCA are the cancer types where MAGED1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Tertile	All	0.483	0.690	<.001	103	view →
UVM	DFS	Median	II,III,IV	0.440	0.733	.001	66	view →
BLCA	DFS	Quartile	II,III,IV	0.300	0.486	.004	41	view →
MESO	OS	Tertile	II,III,IV	0.474	0.714	.008	40	view →
LIHC	OS	Quartile	All	0.576	0.789	<.001	36	view →
PAAD	OS	Median	All	0.693	0.483	.005	36	view →
SARC	OS	Tertile	All	0.473	0.823	<.001	32	view →
ACC	DFS	Quartile	III,IV	0.867	0.100	.001	23	view →
LAML	DFS	Median	All	0.329	0.591	.005	18	view →
LUSC	DFS	Tertile	III,IV	0.225	0.623	.003	17	view →
LGG	DFS	Quartile	All	0.663	0.897	<.001	17	view →
THCA	OS	Median	All	0.964	1.000	.018	14	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 25 lineages.

MAGED1–STAD (OS)

Open the STAD breakdown →